These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 4379915)

  • 21. Solubilization, purification and properties of isocarboxazid hydrolase from guinea pig liver.
    Satoh T; Moroi K
    Biochem Pharmacol; 1972 Dec; 21(23):3111-20. PubMed ID: 4650633
    [No Abstract]   [Full Text] [Related]  

  • 22. Irreversible enzyme inhibitors. LXXXII. Candidate active-site-directed irreversible inhibitors of dihydrofolic reductase. VII. Derivatives of 2,4-diaminopyrimidine. I.
    Baker BR; Jackson GD; Meyer RB
    J Pharm Sci; 1967 May; 56(5):566-70. PubMed ID: 6040577
    [No Abstract]   [Full Text] [Related]  

  • 23. Dihydrofolate reductase of Streptococcus faecalis. I. Purification and some properties of reductase from the wild strain and from strain A.
    Hillcoat BL; Blakley RL
    J Biol Chem; 1966 Jul; 241(13):2995-3001. PubMed ID: 4957970
    [No Abstract]   [Full Text] [Related]  

  • 24. Dihydrofolate reductase from mouse liver and spleen. Purification, properties and inhibition by substituted 2,4-diaminopyrimidines and 4,6-diaminotriazines.
    McCullough JL; Bertino JR
    Biochem Pharmacol; 1971 Mar; 20(3):561-74. PubMed ID: 4402459
    [No Abstract]   [Full Text] [Related]  

  • 25. Gel filtration properties of mutant and wild-type dihydrofolate reductase from Diplococcus pneumoniae.
    Sirotnak FM; Hutchison DJ
    Biochem Biophys Res Commun; 1965 Jun; 19(6):734-8. PubMed ID: 4378809
    [No Abstract]   [Full Text] [Related]  

  • 26. [A new determination method of dihydrofolate reductase using ( 3 H) dihydrofolic acid].
    Schalhorn A; Wilmanns W
    Hoppe Seylers Z Physiol Chem; 1972 Jul; 353(7):1069-74. PubMed ID: 4403737
    [No Abstract]   [Full Text] [Related]  

  • 27. Alteration of the properties of chicken liver dihydrofolate reductase as a result of modification by tetrathionate.
    Barbehenn EK; Kaufman BT
    J Biol Chem; 1980 Mar; 255(5):1978-84. PubMed ID: 7354068
    [No Abstract]   [Full Text] [Related]  

  • 28. Kinetic and chlorine-35 nuclear magnetic resonance studies in the effect of chloride on the properties of chicken liver dihydrofolate reductase.
    Subramanian S; Shindo H; Kaufman BT
    Biochemistry; 1981 May; 20(11):3226-30. PubMed ID: 7248279
    [No Abstract]   [Full Text] [Related]  

  • 29. Purification and properties of 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli.
    Donaldson KO; Scott VF; Scott W
    J Biol Chem; 1965 Nov; 240(11):4444-8. PubMed ID: 4378935
    [No Abstract]   [Full Text] [Related]  

  • 30. Irreversible enzyme inhibitors. LXXXVII. Hydrophobic bonding to dihydrofolic reductase. IX. Mode of binding of m-aryloxyalkyl groups on 4,6-diamino-1,2-dihdro-2,2-dimethyl-1-phenyl-s-triazine.
    Baker BR; Lourens GJ
    J Pharm Sci; 1967 Jul; 56(7):871-5. PubMed ID: 6068108
    [No Abstract]   [Full Text] [Related]  

  • 31. Dialkyl esters of methotrexate and 3',5'-dichloromethotrexate: synthesis and interaction with aldehyde oxidase and dihydrofolate reductase.
    Johns DG; Farquhar D; Wolpert MK; Chabner BA; Loo TL
    Drug Metab Dispos; 1973; 1(3):580-9. PubMed ID: 4149453
    [No Abstract]   [Full Text] [Related]  

  • 32. Irreversible enzyme inhibitors. 133. Studies on differential irreversible inhibition of dihydrofolic reductase from three strains of L1210 leukemia, liver, spleen, and intestine of the mouse.
    Baker BR; Lourens GJ; Meyer RB; Vermeulen NM
    J Med Chem; 1969 Jan; 12(1):67-73. PubMed ID: 5763043
    [No Abstract]   [Full Text] [Related]  

  • 33. Irreversible enzyme inhibitors. CX. Candidate irreversible inhibitors of dihydrofolic reductase derived from 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-s-triazine. IV.
    Baker BR; Lourens GJ
    J Med Chem; 1968 Jan; 11(1):34-7. PubMed ID: 5237172
    [No Abstract]   [Full Text] [Related]  

  • 34. Isolation and characterization of dihydrofolic acid reductase from methotrexate-sensitive and -resistant human cell lines.
    Morandi C; Attardi G
    J Biol Chem; 1981 Oct; 256(19):10169-75. PubMed ID: 7275974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Purification and properties of diphosphopyridine nuleotide-linked isocitrate dehydrogenase of mammalian liver.
    Plaut GW; Aogaichi T
    J Biol Chem; 1968 Nov; 243(21):5572-83. PubMed ID: 4387006
    [No Abstract]   [Full Text] [Related]  

  • 36. Potential antileprotic agents. 2. Inhibition of mycobacterial dihydrofolic reductase.
    DeGraw JI; Brown VH; Colwell WT; Morrison NE
    J Med Chem; 1974 Jan; 17(1):144-6. PubMed ID: 4585973
    [No Abstract]   [Full Text] [Related]  

  • 37. Irreversible enzyme inhibitors. CIX. Candidate irreversible inhibitors of dihydrofolic reductase derived from 4,6-diamino-1,2-dihydro-2,2-dimethyl-1-phenyl-s-triazine. 3.
    Baker BR; Lourens GJ
    J Med Chem; 1968 Jan; 11(1):26-33. PubMed ID: 5237171
    [No Abstract]   [Full Text] [Related]  

  • 38. Calculations by complete neglect of differential overlap (CNDO/2) on dihydrofolic acid: role of N(5) in reduction by dihydrofolate reductase.
    Gund P; Poe M; Hoogsteen KH
    Mol Pharmacol; 1977 Nov; 13(6):1111-5. PubMed ID: 593265
    [No Abstract]   [Full Text] [Related]  

  • 39. [Glutamate dehydrogenase from human liver. Crystallization and biochemical properties].
    Lehmann FG; Pfleiderer G
    Hoppe Seylers Z Physiol Chem; 1969 May; 350(5):609-16. PubMed ID: 4389287
    [No Abstract]   [Full Text] [Related]  

  • 40. Purification and properties of chicken liver D-3-phosphoglycerate dehydrogenase.
    Walsh DA; Sallach HJ
    Biochemistry; 1965 Jun; 4(6):1076-85. PubMed ID: 4378782
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.